Learning Needs of Patients with Cancer and a Pre-Existing Autoimmune Disease Who Are Candidates to Receive Immune Checkpoint Inhibitors

• Published in: Cancers Vol. 15; no. 15; p. 4004
• Main Authors: Lopez-Olivo, Maria A, Kachira, Johncy J, Buni, Maryam, Kim, Sang Taek, Lu, Huifang, Tayar, Jean H, Duhon, Gabrielle F, Ruiz, Juan I, Bingham, 3rd, Clifton O, Calabrese, Cassandra, Volk, Robert J, Suarez-Almazor, Maria E
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 07-08-2023; MDPI
• Subjects: Adverse events; Analysis; Autoimmune diseases; Cancer; Cancer patients; Cancer therapies; Care and treatment; Data collection; Decision making; Development and progression; Disease; Disease management; Drug therapy; Immune checkpoint inhibitors; Interviews; Medical research; Medicine, Experimental; Melanoma; Patient education; Patients; Qualitative research; autoimmune diseases; patient education; qualitative interviews; immunotherapy
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers15154004

Patients with pre-existing autoimmune disorders and cancer considering immune checkpoint inhibitors (ICIs) need to receive balanced information about the benefits and risk of developing immune-related adverse events (irAEs) and flare-ups of their autoimmune disease. To assess the learning needs of patients with cancer and pre-existing autoimmune disease regarding ICI treatment, we interviewed 29 patients with autoimmune disease and cancer from a comprehensive cancer center, of whom 20 had received ICI and 9 were candidates to receive ICI at a US Cancer Center. In-depth semi-structured interviews were conducted from August 2021 and January 2022. Interviewee's opinions and preferences about content and information delivery methods were collected. We recorded and transcribed interviews and analyzed them using thematic analysis. Half of the participants were female, and their median (SD) age was 62.9 (±10.9) years. The identified health information needs included the following: (1) information on irAEs and autoimmune disease flare-ups; (2) benefits of ICI; (3) ICI mechanism in the context of autoimmune disease; (4) management of flare-ups; (5) reasons for stopping or modifying cancer or autoimmune disease treatment; (6) likelihood of autoimmune disease progression or organ damage; and (7) lifestyle changes that could help avoid irAEs. Patients who had received ICI and those who had not yet received treatment reported similar needs, although patients who had received ICI had more questions about cancer treatment modifications. Patients also expressed the need to better understand when to contact their provider and how to share information with multiple providers. Most patients wanted to receive information in visual formats for review at home and at their own pace. Patients expressed interest in having educational tools to facilitate shared decision-making with their physicians, and they identified several areas of health information concerning therapy with ICI. They also highlighted the importance of communication among their various providers.